![Will West](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Will West
Keine laufenden Positionen mehr
Karriereverlauf von Will West
Ehemalige bekannte Positionen von Will West
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Odontis Ltd.
![]() Odontis Ltd. Miscellaneous Commercial ServicesCommercial Services Odontis is developing a biological replacement tooth product - the BioToothTM. The research is lead by Professor Paul Sharpe at King's College London Dental Institute. His team has demonstrated that tooth development can be initiated in stem cells, and that fully formed teeth can be created in developmental models. This is pioneering in that it represents one of the very few examples of a fully integrated tissue engineered organ. The technology opens the potential for the implantation of cultured cells in patients to grow and replace damaged or missing teeth. Odontis has attracted over £2 million of funding to date to progress the technology to commercial development. | Corporate Officer/Principal | 20.11.2009 | 18.01.2011 |
Procter & Gamble Health & Beauty Care | Corporate Officer/Principal | - | - |
Ausbildung von Will West
London Business School | Masters Business Admin |
Statistik
International
Vereinigtes Königreich | 3 |
Vereinigte Staaten | 2 |
Operativ
Corporate Officer/Principal | 2 |
Masters Business Admin | 1 |
Sektoral
Commercial Services | 2 |
Miscellaneous | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Odontis Ltd.
![]() Odontis Ltd. Miscellaneous Commercial ServicesCommercial Services Odontis is developing a biological replacement tooth product - the BioToothTM. The research is lead by Professor Paul Sharpe at King's College London Dental Institute. His team has demonstrated that tooth development can be initiated in stem cells, and that fully formed teeth can be created in developmental models. This is pioneering in that it represents one of the very few examples of a fully integrated tissue engineered organ. The technology opens the potential for the implantation of cultured cells in patients to grow and replace damaged or missing teeth. Odontis has attracted over £2 million of funding to date to progress the technology to commercial development. | Commercial Services |
Procter & Gamble Health & Beauty Care | Miscellaneous |